What Happened?
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 5.4% in the afternoon session after the company reported strong first-quarter 2026 financial results that surpassed analyst expectations on the top and bottom lines.
For the quarter, Jazz announced total revenue of $1.07 billion, a 19.1% increase year on year, which beat Wall Street's estimates by 9.4%. The growth was attributed to strong performance across the company's diversified portfolio. The company's profitability was a highlight, with adjusted earnings per share (EPS) of $6.34 soaring 36.2% above the analyst consensus.
However, the report was not entirely positive, as the company's reaffirmed full-year revenue guidance of $4.38 billion at the midpoint came in below analysts' forecasts. Despite the soft guidance, investors appeared to focus on the significant outperformance in the quarter's revenue and earnings.
After the initial pop the shares cooled down to $222.08, up 4.6% from previous close.
Is now the time to buy Jazz Pharmaceuticals? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Jazz Pharmaceuticals’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 18.3% on the news that the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its cancer drug, Ziihera.
The study tested Ziihera as a first-line treatment for patients with a type of advanced or metastatic gastroesophageal cancer. The trial found that Ziihera, when used with chemotherapy, led to statistically significant and clinically meaningful improvements in progression-free survival compared to the current standard treatment. This means the drug helped patients live longer without their cancer getting worse.
Furthermore, when Ziihera was combined with chemotherapy and the checkpoint inhibitor tislelizumab, it also showed a significant improvement in overall survival rates. These strong results suggested that Ziihera-based treatments could become a new standard of care for this form of cancer.
Jazz Pharmaceuticals is up 28.3% since the beginning of the year, and at $222.08 per share, has set a new 52-week high. Investors who bought $1,000 worth of Jazz Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,285.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.